D-3699 Dovitinib, Lactate Salt, >99%

Synonyms : [CHIR-258] [TKI-258]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 73
  • 67
  • 57
  • 11,400
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 144
  • 132
  • 113
  • 22,400
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 213
  • 195
  • 167
  • 33,200
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 356
  • 327
  • 280
  • 55,400
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 632
  • 581
  • 497
  • 98,400
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 1,080
  • 993
  • 849
  • 168,100
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 1,770
  • 1,628
  • 1,392
  • 275,500
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 482.51
  • C21H21FN6O•C3H6O3
  • [692737-80-7]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Soluble in DMSO at 25 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility.
  • Dovitinib inhibited proliferation of ZNF198-FGFR1 and BCR-FGFR1 transformed Ba/F3 cells with IC50 values of 150 nM and 90 nM, respectively. The phosphorylation of each fusion gene, ERK, and STAT5 was inhibited as well at the same time. Dovitinib also inhibited proliferation of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines and induced apoptosis. Furthermore, dovitinib significantly inhibited the growth of primary cells from 8p11 myeloproliferative syndrome (EMS) patients dose-dependently. Chase, A., et al. "Activity of TKI258 against primary cells and cell lines with FGFR1-fusion genes associated with the 8p11 myeloproliferative syndrome." Blood 110: 3729-3734 (2007).
  • Dovitinib potently inhibits receptor tyrosine kinases including FLT3, c-KIT, CSF-1R/c-fms, FGFR1, FGFR3, VEGFR1/Flt1,VEGFR2/Flk1, VEGFR3/Flt4, PDGFRβ, and PDGFRα with IC50 values of 1, 2, 36, 8, 9, 10, 13, 8, 27, and 210 nM, respectively. Dovitinib selectively blocked the growth of wild-type (WT) or activated mutant FGFR3-transformed B9 cells and human myeloma cell lines. Dovitinib was an effective treatment in a xenograft mouse model of FGFR3 multiple myeloma (MM). Trudel, S., et al. "CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma." Blood 105: 2941-2948 (2005).
  • Dovitinib treatment showed antitumor and antiangiogenic activities in xenograft models of human colon cancer. Dovitinib inhibited vascular endothelial growth factor receptor 1/2, fibroblast growth factor receptor 1/3, platelet-derived growth factor receptor β (PDGFR-β), the phosphorylation of PDGFR-β and extracellular signal-regulated kinase (ERK) in tumors. Lee, S.H., et al. "In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models." Clin. Cancer Res. 11: 3633-3641 (2005).
  • Dovitinib was examined on two human leukemic cell lines with differing FLT3 mutational status in vitro and in vivo, including MV4;11 cells expressing FLT3 internal tandem duplications (ITD) and RS4;11 cells with wild-type (WT) FLT3. Antiproliferative activity of dovitinib against MV4;11 was about 24-fold greater than against RS4;11. Lopes de Menezes, D.E., et al. "CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia." Clin. Cancer Res. 11: 5281-5291 (2005).
  • Dovitinib significantly inhibited KMS-11-luc tumor growth and improved animal survival at doses that inhibited FGFR3 signaling in KMS-11-luc tumors in vivo. Xin, X., et al. "CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice." Clin. Cancer Res. 12: 4908-4915 (2006).
  • This research compound is the lactate salt form of dovitinib.  Please see the free base form of dovitinib,  Cat. No. D-3608, Dovitinib, Free Base, for further technical information.
  • This dovitinib product is the free lactate salt whose CAS number is given above.  The CAS number of the free base is 405169-16-6
  • The CAS number for the monohydrate of dovitinib lactate salt is 915769-50-5.
  • Another CAS number previously assigned to dovitinib lactate, namely 1000873-96-0, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.